US 12,064,419 B2
Methods of using RAD51 inhibitors for treatment of pancreatic cancer
Alfredo C. Castro, Woburn, MA (US); Melinda Day, Sudbury, MA (US); Tyler Maclay, Somerville, MA (US); Casey Cameron McComas, Phoenixville, PA (US); Kevin Mills, Acton, MA (US); and Joseph Vacca, Telford, PA (US)
Assigned to Cyteir Therapeutics, Inc., Lexington, MA (US)
Filed by Cyteir Therapeutics, Inc., Lexington, MA (US)
Filed on Jun. 22, 2020, as Appl. No. 16/907,430.
Claims priority of provisional application 62/895,138, filed on Sep. 3, 2019.
Claims priority of provisional application 62/864,861, filed on Jun. 21, 2019.
Prior Publication US 2020/0397760 A1, Dec. 24, 2020
Int. Cl. A61K 31/426 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/426 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)] 16 Claims
 
1. A method of treating pancreatic cancer, the method comprising administering to a subject in need thereof an effective amount of Compound 67A:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, at a dosage ranging from about 250 mg/day to about 500 mg/day, wherein Compound 67A is the sole therapeutic agent.